Dapansutrile

Dapansutrile was first characterized as a specific NLRP3 inflammasome inhibitor in a 2018 study showing that nanomolar concentrations reduced interleukin-1 beta and interleukin-18 release after canonical and noncanonical NLRP3 activation, without affecting the AIM2 or NLRC4 inflammasomes; the same work reported that healthy humans taking 1000 mg daily for 8 days had no adverse biochemical or hematological changes.

In an open-label phase 2a proof-of-concept trial, oral dapansutrile at doses from 100 to 2000 mg per day reduced patient-reported gout flare joint pain by roughly 80 percent by day 7 across dose groups, with a satisfactory safety profile. A phase 1B randomized, double-blind study in patients with New York Heart Association class II to III systolic heart failure found 14 days of treatment safe and well tolerated, with signals of improved left ventricular ejection fraction and exercise time in the highest-dose cohort.

Preclinical neuroscience data are extensive: dapansutrile rescued cognitive impairment and synaptic plasticity in an APP/PS1 Alzheimer mouse model while reducing microglial activation and plaque burden; ameliorated experimental autoimmune encephalomyelitis, a model of multiple sclerosis, protecting against demyelination and lowering spinal-cord cytokines; and improved functional recovery and myelin preservation after spinal cord injury. In progeroid mice it reduced progerin accumulation, senescence, and inflammation and extended lifespan, improving the therapeutic action of lonafarnib. Across these studies the mechanism is consistent: selective interference with NLRP3 oligomerization and ATPase activity rather than broad cytokine blockade.

In early human studies dapansutrile has been well tolerated. Healthy volunteers dosed at 1000 mg daily for 8 days showed no adverse biochemical or hematological changes, and phase 1B and phase 2a trials reported no drug-related serious adverse events. The most common treatment-emergent effects in the gout trial were metabolism, nutrition, and gastrointestinal disorders. Because the compound dampens a branch of innate immunity, a theoretical concern is reduced host defense with prolonged use, and long-term human safety has not been established. It remains investigational and is not an approved medicine.

Dapansutrile was developed by Olatec Therapeutics as OLT1177. Its NLRP3-selective mechanism was defined in a 2018 study led by Marchetti and Dinarello, and it subsequently advanced into human trials for acute gout flares, systolic heart failure, and inflammatory conditions, becoming one of the earliest orally active NLRP3 inhibitors shown to be safe in people.

Within inflammation research, dapansutrile is regarded as a landmark orally bioavailable NLRP3 inhibitor with a clean early human safety record. In nootropic and longevity communities it draws interest for its neuroinflammation and anti-senescence data, though it is a clinical-stage investigational drug rather than a consumer supplement, and access is limited.